Search

Displaying results 1201 - 1210 of 5261 in total
  1. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    This approval was based on favorable results obtained from the phase III APPL-PNH and APPOINT-PNH studies, where 82.3% and 77.5% of patients experienced a sustained hemoglobin improvement without transfusions … [A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH.

  2. Drug

    Deslanoside

    go.drugbank.com/drugs/DB01078
    Approved

    A cardiotonic glycoside from the leaves of Digitalis lanata.

  3. Drug

    Hydroflumethiazide

    go.drugbank.com/drugs/DB00774
    ApprovedWithdrawn

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)

  4. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL,[ … L10166] which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug.

  5. Drug

    Mometasone furoate

    go.drugbank.com/drugs/DB14512
    ApprovedInvestigationalVet approved

    Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions[FDA Label] . It has a glucocorticoid receptor binding affinity 22 times stronger than dexamethasone and highe...

    Mixtures: DIRNELID-AZ
  6. Drug

    Niclosamide

    go.drugbank.com/drugs/DB06803
    ApprovedInvestigationalVet approved

    Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.[L11860]

  7. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.

  8. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    Fosnetupitant is the pro-drug form of netupitant [FDA label].

  9. Drug

    Mecasermin rinfabate

    go.drugbank.com/drugs/DB14751
    ApprovedInvestigational

    Mecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005[L5722].

  10. Drug

    Testosterone enanthate

    go.drugbank.com/drugs/DB13944
    ApprovedInvestigational

    This slow release is achieved by the presence of the enanthate ester functional group attached to the testosterone molecule.